eNeura’s SpringTMS migraine treatment receives positive NICE guidance

eNeura, a medical technology company, has announced that the UK National Institute for Health and Care Excellence (NICE) has published interventional procedure guidance recommending transcranial magnetic stimulation (TMS) for the treatment of migraine.

The new guidelines are based on a thorough technology appraisal, which includes assessments for product safety and efficacy for routine use, and are designed to support the National Health Service (NHS) in the process of introducing new procedures in a responsible way.

eNeura’s patented SpringTMS device is the only portable single pulse TMS device clinically proven effective in the treatment of migraine. The device received CE marking in Europe for the acute treatment of migraine and is available by prescription in the UK.

eNeura president and CEO David K Rosen noted NICE’s independent, authoritative and evidence-based guidelines advise NHS on the most effective ways to prevent, diagnose and treat disease and ill health.

"The issuance of guidance regarding TMS for the treatment of migraine is an encouraging validation for our technology, as NHS will only consider routine use of any treatment with NICE guidance first being established.

"In the UK alone, millions of people suffer from migraine, many without safe effective treatment options and we view NICE’s guidance as a critical step in expanding the use of SpringTMS to reach this patient population," Rosen added.

SpringTMS is the only patient use TMS device available in the UK to treat migraine. The user applies TMS to the back of the head using both hands and presses a button to generate a focused, single pulse of magnetic energy that treats the migraine headache non-invasively and without discomfort.

Consultant neurologist Dr Fayyaz Ahmed noted this is a breakthrough treatment for those who cannot tolerate or do not respond to current treatment, and opens the door for a new era in treating migraine headaches.

"We welcome NICE guidance and very much hope this treatment is made available to those in need," Dr Ahmed added.